Utah Medical Products (UTMD)
(Delayed Data from NSDQ)
$69.64 USD
+0.87 (1.27%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $70.08 +0.44 (0.63%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UTMD 69.64 +0.87(1.27%)
Will UTMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for UTMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTMD
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales
Zacks Initiates Coverage of UTMD With Neutral Recommendation
UTMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace
Top Stock Reports for Apple, Mastercard & Amgen
Other News for UTMD
UTMD Stock Earnings: Utah Medical Products Reported Results for Q2 2024
Utah Medical: Q2 Earnings Snapshot
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024
Utah Medical Products reports Q2 EPS 97.8c vs. $1.154 last year
UTMD Makes Bullish Cross Above Critical Moving Average